摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-O-乙酰基乌苏基脱氧胆酸甲酯 | 75672-24-1

中文名称
7-O-乙酰基乌苏基脱氧胆酸甲酯
中文别名
7-O-乙酰熊去氧胆酸甲基酯
英文名称
methyl ursodeoxycholate 7-acetate
英文别名
methyl 7-acetylursodeoxycholate;7-O-Acetyl Ursodeoxycholic Acid Methyl Ester;methyl (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-7-acetyloxy-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
7-O-乙酰基乌苏基脱氧胆酸甲酯化学式
CAS
75672-24-1
化学式
C27H44O5
mdl
——
分子量
448.643
InChiKey
PMJBQFRZSVOFFB-HGDNJWNYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    53-61°C
  • 沸点:
    518.9±25.0 °C(Predicted)
  • 密度:
    1.10±0.1 g/cm3(Predicted)
  • 溶解度:
    可溶于二氯甲烷、甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    32
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.93
  • 拓扑面积:
    72.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-O-乙酰基乌苏基脱氧胆酸甲酯N-溴代丁二酰亚胺(NBS)三苯基膦 作用下, 以 四氢呋喃 为溶剂, 以91%的产率得到24-methyl 3β-bromo-7β-acetoxy-5β-cholanoate
    参考文献:
    名称:
    Bile acid toxicity structure–activity relationships: Correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A)
    摘要:
    The molecular mechanisms and interactions underlying bile acid cytotoxicity are important to understand for intestinal and hepatic disease treatment and prevention and the design of bile acid-based therapeutics.Bile acid lipophilicity is believed to be an important cytotoxicity determinant but the relationship is not well characterized. In this study we prepared new azido and other lipophilic BAs and altogether assembled a panel of 37 BAs with good dispersion in lipophilicity as reflected in RPTLC R-Mw. The MTT cell viability assay was used to assess cytotoxicity over 24 h in the HET-1A cell line (oesophageal). RMw values inversely correlated with cell viability for the whole set (r(2) = 0.6) but this became more significant when non-acid compounds were excluded (r(2) = 0.82, n = 29). The association in more homologous subgroups was stronger still (r(2) > 0.96). None of the polar compounds were cytotoxic at 500 mu M, however, not all lipophilic BAs were cytotoxic. Notably, apart from the UDCA primary amide, lipophilic neutral derivatives of UDCA were not cytotoxic. Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by R-Mw. In a hepatic carcinoma line, lipophilicity did not correlate with toxicity except for the common naturally occurring bile acids and their conjugates. There were other significant differences in toxicity between the two cell lines that suggest a possible basis for selective cytotoxicity. The study shows: (i) azido substitution in BAs imparts lipophilicity and toxicity depending on orientation and ionizability; (ii) there is an inverse correlation between R-Mw and toxicity that has good predictive value in homologous sets; (iii) lipophilicity is a necessary but apparently not sufficient characteristic for BA cytocidal activity to which it appears to be indirectly related. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.07.030
  • 作为产物:
    描述:
    3alpha,7beta-二-O-乙酰基乌苏基脱氧胆酸甲酯甲醇 、 sodium hydroxide 作用下, 反应 0.5h, 以85%的产率得到7-O-乙酰基乌苏基脱氧胆酸甲酯
    参考文献:
    名称:
    一种3β-熊去氧胆酸的制备方法
    摘要:
    本发明公开了一种3β‑熊去氧胆酸的合成方法,采用熊去氧胆酸为原料,经过酯化,保护3、7位羟基,选择性脱除3位保护基,氧化3位羟基,然后还原为3β羟基,水解7位、24位保护基得到所述3β‑熊去氧胆酸。本发明合成方法新颖,成本较低,产率高,条件温和,操作简便,环境友好。
    公开号:
    CN109912676B
点击查看最新优质反应信息

文献信息

  • Synthesis of 3-glucuronides of unconjugated and conjugated bile acids.
    作者:JUNICHI GOTO、KAZUHIKO SUZAKI、TOSHIO NAMBARA
    DOI:10.1248/cpb.28.1258
    日期:——
    The 3-glucuronides of unconjugated, glyco- and tauro-conjugated bile acids have been prepared by an unequivocal route. Among three synthetic routes leading to the desired compounds, a method involving glucuronidation of the p-nitrophenyl ester by means of the Koenigs-Knorr reaction and subsequent conversion of the activated ester into the glyco-and tauro-conjugates was found to be most suitable. The nuclear magnetic resonance spectral data for bile acid glucuronides and related compounds are tabulated.
    非结合胆汁酸、糖结合胆汁酸和牛磺结合胆汁酸的 3-葡萄糖醛酸苷是通过一种明确的途径制备出来的。在获得所需化合物的三种合成路线中,通过柯尼希斯-克诺尔(Koenigs-Knorr)反应对硝基苯酯进行葡萄糖醛酸化,然后将活化的酯转化为糖型和牛磺酸型共轭物的方法最为合适。胆汁酸葡萄糖醛酸和相关化合物的核磁共振光谱数据已列表。
  • Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis
    作者:Cristina Di Giorgio、Elva Morretta、Antonio Lupia、Rachele Bellini、Carmen Massa、Ginevra Urbani、Martina Bordoni、Silvia Marchianò、Ginevra Lachi、Pasquale Rapacciuolo、Claudia Finamore、Valentina Sepe、Maria Chiara Monti、Federica Moraca、Nicola Natalizi、Luigina Graziosi、Eleonora Distrutti、Michele Biagioli、Bruno Catalanotti、Annibale Donini、Angela Zampella、Stefano Fiorucci
    DOI:10.1016/j.bcp.2024.116134
    日期:2024.5
    metabolism and the intestinal microbiota. Here we demonstrated that bile acids serve as endogenous antagonist to LIFR in oncogenesis. The tissue characterization of bile acids content in non-cancer and cancer biopsy pairs from gastric adenocarcinomas (GC) demonstrated that bile acids accumulate within cancer tissues, with glyco-deoxycholic acid (GDCA) functioning as negative regulator of LIFR expression.
    白血病抑制因子 (LIF) 是白细胞介素 (IL)-6 细胞因子家族的成员,参与免疫调节、形态发生和肿瘤发生。在癌组织中,LIF 结合由 LIFRβ 亚基和糖蛋白 (gp) 形成的异二聚体受体 (LIFR)130,促进上皮间充质转化和细胞生长。胆汁酸是在宿主代谢和肠道微生物群界面处产生的胆固醇代谢物。在这里,我们证明了胆汁酸在肿瘤发生中是 LIFR 的内源性拮抗剂。胃腺癌 (GC) 非癌和癌症活检对中胆汁酸含量的组织表征表明,胆汁酸在癌组织内积累,其中糖脱氧胆酸 (GDCA) 作为 LIFR 表达的负调节因子。在来自 GC 患者的患者来源类器官 (hPDO) 中,GDCA 可逆转 LIF 诱导的干性和增殖。总之,我们已经确定次级胆汁酸是 LIFR 的第一个内源性拮抗剂,支持在 LIF 介导的肿瘤发生中开发基于胆汁酸的疗法。
  • Synthesis of N-acetylglucosaminides of unconjugated and conjugated bile acids
    作者:Niwa Toshifumi、Koshiyama Tomoyoshi、Goto Junichi、Nambara Toshio
    DOI:10.1016/0039-128x(92)90021-z
    日期:1992.11
    3-N-Acetylglucosaminides of unconjugated, glycine- and taurine-conjugated bile acids have been synthesized. Bile acids appropriately protected were condensed with acetochloroglucosamine through the 3 alpha-hydroxyl group by means of the Koenigs-Knorr reaction using cadmium carbonate as a catalyst. Subsequent borohydride reduction and/or alkaline hydrolysis provided desired 3-N-acetylglucosaminides of unconjugated bile acids. Glycine-conjugates were obtained from N-acetylglucosaminides of unconjugated bile acids and ethyl glycinate by the carbodiimide method. The preparation of N-acetylglucosaminides of taurine-conjugates was attained by the Koenigs-Knorr reaction of bile acid p-nitrophenyl esters followed by condensation with taurine. 7-N-Acetylglucosaminides of ursodeoxycholates were prepared in a similar fashion. The convenient synthesis of 3-N-acetylglucosaminides of unconjugated bile acids is also described.
  • Novel liver-specific nitric oxide (NO) releasing drugs with bile acid as both NO carrier and targeting ligand
    作者:Xue-Yuan Jin、Shi-Yong Fan、Hong-Wu Li、Wei-Guo Shi、Wei Chen、Hui-Fen Wang、Bo-Hua Zhong
    DOI:10.1016/j.cclet.2014.04.001
    日期:2014.5
    Novel liver-specific nitric oxide (NO) releasing drugs with bile acid as both the NO carrier and targeting ligand were designed and synthesized by direct nitration of the hydroxyl group in bile acids or the 3-O-hydroxyl alkyl derivatives, with the intact 24-COOH being preserved for hepatocyte specific recognition. Preliminary biological evaluation revealed that oral administrated targeted conjugates could protect mice against acute liver damage induced by acetaminophen or carbon tetrachloride. The nitrate level in the liver significantly increased after oral administration of 1e while nitrate level in the blood did not significantly change. Co-administration of ursodeoxycholic acid (UDCA) significantly antagonized the increase of nitrate in the liver resulted by administration of 1e. (C) 2014 Hui-Fen Wang and Bo-Hua Zhong. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B